Makar, Tapas K.
Guda, Poornachander R.
Ray, Sugata
Andhavarapu, Sanketh
Keledjian, Kaspar
Gerzanich, Volodymyr
Simard, J. Marc
Nimmagadda, Vamshi K. C.
Bever, Christopher T. Jr
Funding for this research was provided by:
Teva Pharmaceutical Industries,Israel
Article History
Received: 21 July 2022
Accepted: 11 February 2023
First Online: 6 April 2023
Competing interests
: Partial funding for the study was provided by an investigator-initiated grant to Dr. Makar from Teva Neuroscience, Inc. which markets glatiramer acetate as a treatment for multiple sclerosis. Guda declares no competing interests. Ray declares no competing interests. Andhavarapu declares no competing interests. Keledjian declares no competing interests. Gerzanich declares no competing interests. Simard declares no competing interests. Nimmagadda declares no competing interests. Bever declares no competing interests.